Ju Hyun Shim
Clinical trials sponsored by Ju Hyun Shim, explained in plain language.
-
New hope for liver cancer patients with limited options after immunotherapy fails
Disease control Not yet recruitingThis study tests the drug regorafenib in about 20 adults with advanced liver cancer and moderate liver impairment (Child-Pugh B) whose cancer worsened after first-line immunotherapy. Participants take regorafenib pills daily for 3 weeks, then 1 week off, until the cancer progress…
Phase: PHASE2 • Sponsor: Ju Hyun Shim • Aim: Disease control
Last updated May 17, 2026 06:47 UTC
-
Second-line hope for liver cancer: regorafenib tested after lenvatinib failure
Disease control Not yet recruitingThis study tests a drug called regorafenib in about 24 adults with advanced liver cancer that did not respond to the first treatment, lenvatinib. The goal is to see if regorafenib can slow tumor growth and improve survival. Participants will take regorafenib pills and have regula…
Phase: PHASE2 • Sponsor: Ju Hyun Shim • Aim: Disease control
Last updated May 15, 2026 11:56 UTC